Canada approves BioCurex' Histo-RECAF cancer diagnostic:
This article was originally published in Clinica
Executive Summary
Canada has approved for sale BioCurex' Histo-RECAF diagnostic test kit for detecting cancers of the breast, lung, stomach, prostate and lymph node tissues. The test, which can detect malignant cancers from blood or tissue samples, is based on the identification of a common cancer biomarker, known as RECAF. The Rancho Santa Margarita, California firm says that research has shown the test to have a sensitivity of 100% in the detection of breast cancer (see Clinica No 967, p 17). It adds that it will also file for approval in other strategic markets shortly.